Expert Interview
Discussing the potential of gene therapies for sickle cell disease including Vertex and CRISPR Therapeutics' Casgevy (Exa-cel) and Bluebird bio's Lyfgenia (lovotibeglogene autotemcel)
Ticker(s): VRTX, CRSPInstitution: University of Texas Southwestern Medical Center
- Emerius Professor of Pediatrics in the Division of Hematology/Oncology at the University of Texas Southwestern Medical Center in Dallas
- 40 years experience in the care of pediatric patients with sickle cell disease including participation in 2 NIH:NHLBI funded Comprehensive Sickle Cell Disease Centers.
- Current activities specifically include vice chair of NIH:NHLBI DSMB #1 for bone marrow transplantation and other cellular therapies in sickle cell disease and hematology and grant review for participating centers
Do you prefer a certain gene therapy over the other and why?
Added By: sara_adminDo you expect both gene therapies to be equally successful going forward or do you believe one will be more prescribed over they other?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of Casgevy, what would it be and why?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of Lyfgenia, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
